Calcific aortic valve disease (CAVD) is a widely prevalent heart disorder in need of pharmacological interventions. Calcified areas in aortic valves often contain amyloid fibrils that promote calcification in vitro. This opinion paper suggests that amyloid contributes to CAVD development; amyloid-assisted nucleation can accelerate hydroxyapatite deposition onto collagen matrix. Notably, acidic arrays in amyloid match calcium-calcium spacing in the amorphous hydroxyapatite precursor, while oscillating hemodynamic perturbations promote amyloid deposition in the valve. Lipoprotein(a), a genetic risk factor for CAVD, augments calcification via several mechanisms, wherein hydrolysis of oxidized phospholipids (oxPLs) by Lp(a)-associated enzymes helps generate orthophosphate, and apolipoprotein(a) blocks plasmin-induced fibril degradation. Current studies of amyloid-calcium-collagen interactions in solution and in fibrillar complexes allow deeper insight into the role of amyloid in calcification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563925 | PMC |
http://dx.doi.org/10.1016/j.molmed.2024.04.015 | DOI Listing |
Interdiscip Cardiovasc Thorac Surg
December 2024
Department of Cardiovascular Surgery, Kitasato University Hospital, Japan.
Objectives: The objective of this study was to evaluate the impact of minimally invasive extracorporeal circulation on blood transfusion and asymptomatic brain injury in comparison to conventional extracorporeal circulation, in the context of minimally invasive aortic valve replacement through right lateral mini-thoracotomy surgery.
Methods: This was a retrospective observational study. Patients who underwent isolated aortic valve replacement through right lateral mini-thoracotomy surgery were divided into two groups: the minimally invasive extracorporeal circulation group and the conventional extracorporeal circulation group.
Radiol Cardiothorac Imaging
February 2025
From the University Medical Center Göttingen, Department of Cardiology and Pneumology, Georg-August University, Robert-Koch-Strasse 40, 37075 Göttingen, Germany (T.L., B.E.B., A. Schulz, R.E., K.R.R., K.T., G.H., M.P., A. Schuster); German Center for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany (T.L., B.E.B., A. Schulz, R.E., K.R.R., K.T., G.H., M.P., A. Schuster); Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass (A. Schulz); Department of Cardiology, Campus Kerckhoff of the Justus-Liebig-University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany (S.J.B.); German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Bad Nauheim, Germany (S.J.B.); FORUM Radiology, Rosdorf, Germany (J.T.K.); Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany (G.H.); and FORUM Cardiology, Rosdorf, Germany (A. Schuster).
Purpose To assess the prognostic implications of cardiac MRI-derived imaging markers in individuals with severe aortic stenosis (AS). Materials and Methods This prospective study (German Clinical Trials Register, DRKS00024479) enrolled individuals with severe AS who underwent cardiac MRI before transcatheter aortic valve replacement (TAVR) from January 2017 to March 2022. Image analyses included myocardial volumes, cardiac MRI feature tracking-derived left atrial (LA) and right atrial (RA) as well as left ventricular (LV) and right ventricular (RV) strain, myocardial T1 mapping, and late gadolinium enhancement analyses.
View Article and Find Full Text PDFEur Heart J
January 2025
Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
JTCVS Open
December 2024
Department of Cardiovascular Surgery, Jefferson Health, Philadelphia, Pa.
Objective: To compare outcomes of aortic valve replacement (AVR) in patients with pure aortic stenosis (Pure AS) and those with pure aortic regurgitation (Pure AR) or mixed AS and AR (MAVD) in the COMMENCE trial.
Methods: Of 689 patients who underwent AVR in the COMMENCE trial, patients with moderate or severe AR with or without AS (Pure AR + MAVD; n = 135) or Pure AS (n = 323) were included. Inverse probability of treatment weighting Kaplan-Meier survival curves were used for time-to-event endpoints, and longitudinal changes in hemodynamics were evaluated using mixed-effects models.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!